Has Jannice Arroyo Soto, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,770 in general payments to Jannice Arroyo Soto, MD across 109 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jannice Arroyo Soto, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jannice Arroyo Soto, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jannice Arroyo Soto, MD

Nephrology · Ponce, PRNPI 1710288550

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.6% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AstraZeneca at 29.9% of the total. 2025 is the largest year on record at $1,294, 2.3 times the $562 reported in 2019.

$4,770in general payments, 2019–2025

Across 109 payments — averaging $43.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$1K
Bayer Puerto Rico Inc.$648
Bayer$620
Boehringer Ingelheim$450
Johnson & Johnson$298
Amgen$218
plus $1K from 11 others

What the payments were for

Food & beverage$4,46494%
Education$3066%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	35	$1,426
Bayer Puerto Rico Inc.	22	$648
Bayer	9	$620
Boehringer Ingelheim	9	$450
Johnson & Johnson	5	$298
Amgen	4	$218
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	9	$164
Vifor Pharma, Inc.	2	$150
E.r. Squibb & Sons, L.L.C.	2	$139
Calliditas Therapeutics US Inc.	4	$125
Dexcom, Inc.	1	$114
Mallinckrodt Hospital Products Inc.	1	$100
Mallinckrodt Enterprises LLC	1	$99
Sanofi-aventis U.S. LLC	1	$91
GSK	1	$72
Eli Lilly Export S.A. Puerto Rico Branch	2	$39
Novartis	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,770 in reported general payments places this provider in the 85th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$14,647

Medicare patients

Services billed

160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
FarxigaDapagliflozin Propanediol	257	$158,980
JardianceEmpagliflozin	75	$47,928
Lanthanum Carbonate	43	$38,895
KerendiaFinerenone	30	$19,892
LokelmaSodium Zirconium Cyclosilicate	20	$16,823
Sevelamer Carbonate	101	$13,561
Sodium Polystyrene Sulfonate	29	$4,193
Calcitriol	253	$3,273
Allopurinol	249	$1,704
LantusInsulin Glargine,hum.Rec.Anlog	17	$1,141
Calcium Acetate	11	$892
Losartan Potassium	98	$855
Valsartan	24	$672
Famotidine	102	$658
Furosemide	87	$584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AstraZenecaFarxiga, Lokelma	$1,426	$175,803277 claims
Boehringer IngelheimJardiance	$450	$47,92875 claims
BayerKerendia	$620	$19,89230 claims
Sanofi-aventis U.S. LLCLantus	$91	$1,14117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in Ponce

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →